摘要
大量的临床研究发现,肥胖程度与甲状腺功能的变化有关,而肥胖与甲状腺功能状态的改变熟因熟果目前尚存争论。肥胖症患者甲状腺功能的变化可能会引起心血管疾病风险的增加和胰岛素抵抗的加重。此外,肥胖症患者罹患结节性甲状腺肿和亚临床甲状腺功能减退的概率也明显上升,肥胖所致的低度炎症状态和内源性激素的分泌增加可能参与了甲状腺局部免疫状态的变化。虽然目前并不推荐甲状腺激素用作肥胖症的治疗,但是甲状腺激素的类似物GC-1为这一设想带来了新的希望。
Lots of clinical studies found that obesity was associated with thyroid dysfunction, though the mechanism remains to be determined. Changes of thyroid function in obese patients may increase the risk of cardiovascular disease and insulin resistance. Recent studies have shown that the incidence of nodular goiter and subclinical hypothyroidism was also increased in obesity. The slight inflammatory state induced by obesity and abnormal endogenous hormone secretion may be involved in local immunological alterations in the thyroid gland and lead to thyroid dysfunction and nodular goiter. Although thyroxine is not recommend to treat obesity, its synthetic analogue named GC-1 brings new hope to this design.
出处
《国际内科学杂志》
CAS
2009年第12期715-717,738,共4页
International Journal of Internal Medicine
